Akamai Technologies (AKAM) CEO Dr. Tom Leighton is putting his money where his mouth is. Right now that’s got him smiling. After Akamai beat Wall Street analyst estimates on the top and bottom lines in its fourth quarter, Leighton announced his plan to buy $10 million in Akamai shares in the next six months. Those shares became more expensive, however, as the stock soared over 22% Wednesday after the company announced its 2015 fourth quarter earnings and a $1 billion share buyback plan to cover compensation costs. “I am really excited about Akamai,” said Leighton. “We are really profitable. We are growing rapidly. We have a great market position and a ton of potential for future growth.” For the most recent quarter, Akamai posted adjusted earnings of $0.72 cents a share, higher than analysts' estimates for $0.61 cents a share. Revenue was $579.2 million, beating analysts' expectations for $567.1 million.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.